In this study, we determined diatrizoate concentrations in plasma and the extravascular space in dogs following an injection of the same dose of diatrizoate under three different conditions: (A) subsequent to a rapid bolus injection of diatrizoate: (B) subsequent to a bolus injection followed by an intravenous drip infusion; and (C) subsequent to a slow intravenous drip infusion. The data indicate that the highest plasma level occurred immediately after bolus injection (A). Significantly more diatrizoate was present in plasma 10 to 25 min from the start of an intravenous drip infusion given over 12.5 min (C) than when the same dose was given as a rapid bolus (A). The slow infusion method also resulted in significantly higher diatrizoate plasma levels from 15 to 25 min when compared to the bolus plus drip method (B). The differences in the calculated extravascular concentrations were insignificant among the three groups once all of the contrast material had been infused, i.e., after 12.5 min. The results are discussed in terms of their practical application to cranial computed tomography.

Download full-text PDF

Source
http://dx.doi.org/10.1097/00004728-198004000-00008DOI Listing

Publication Analysis

Top Keywords

bolus injection
12
intravenous drip
12
drip infusion
12
rapid bolus
8
injection diatrizoate
8
diatrizoate plasma
8
125 min
8
diatrizoate
6
injection
5
bolus
5

Similar Publications

Pharmacokinetics of remimazolam, midazolam and diazepam in sheep.

Vet Anaesth Analg

December 2024

Department of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, CA, USA; Kenneth L. Maddy Equine Analytical Chemistry Laboratory, School of Veterinary Medicine, University of California, Davis, CA, USA.

Objective: To model pharmacokinetics of three benzodiazepines and their metabolites in sheep.

Study Design: A nonblinded, prospective, experimental study.

Animals: A group of six adult Hampshire-Suffolk cross-bred sheep (three females, three castrated males), 73 ± 3 kg (mean ± standard deviation).

View Article and Find Full Text PDF

Combination therapies using checkpoint inhibitors with immunostimulatory agonists have attracted great attention due to their synergistic therapeutic effects for cancer treatment. However, such combination immunotherapies require specific timing of doses to show sufficient antitumor efficacy. Sequential treatment usually requires multiple administrations of the individual drugs at specific time points, thus increasing the complexity of the drug regimen and compromising patient compliance.

View Article and Find Full Text PDF

Background And Objective: We evaluated the effectiveness of injecting autologous adipose-derived regenerative cells (ADRCs) into plaque in men with chronic Peyronie's disease (PD).

Methods: This pilot safety study recruited 22 Danish men with chronic PD from an outpatient clinic. Patients received one bolus of ADRCs injected into plaque, with follow-ups at 1, 3, 6, and 12 mo.

View Article and Find Full Text PDF

Objective: To investigate the pharmacodynamics and pharmacokinetics of rocuronium administered by bolus injection to sevoflurane-anesthetized horses.

Study Design: Prospective, experimental, crossover study.

Animals: Five healthy adult Thoroughbred horses (body mass 368-470 kg, three females and two males).

View Article and Find Full Text PDF

Efficacy, safety and treatment satisfaction of transition to a regimen of insulin degludec/aspart: A pilot study.

World J Diabetes

January 2025

Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.

Background: There is a lack of clinical evidence on the efficacy and safety of transitioning from a thrice-daily pre-mixed insulin or basal-prandial regimen to insulin deglu-dec/aspart (IDegAsp) therapy, with insufficient data from the Chinese popu-lation.

Aim: To demonstrate the efficacy, safety, and treatment satisfaction associated with the transition to IDegAsp in type 2 diabetes mellitus (T2DM).

Methods: In this 12-week open-label, non-randomized, single-center, pilot study, patients with T2DM receiving thrice-daily insulin or intensive insulin treatment were transitioned to twice-daily injections of insulin IDegAsp.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!